Responsive Image

 

 

Responsive Image

Neuroinmunología

Líneas de investigación

Investigación sobre la historia natural de la enfermedad. Estudio y seguimiento de la "cohorte de pacientes de Esclerosis Múltiple de Vizcaya".
Investigación clínica farmacológica.
Investigación clínica sobre la evolución natural de la enfermedad en determinadas circunstancias (EM y embarazo, EM en pacientes pediátricos, EM y circunstancias relacionadas con el género, EM y co-morbilidad).
Investigación clínica e integración asistencial con atención primaria mediante el "protocolo Bilbao".
Estrategia conjunta de cooperación-comunicación entre distintos niveles asistenciales, en este caso, neurología y atención primaria para mejorar la eficiencia y la calidad asistencial.
Investigación sobre la comorbilidad de esta patología crónica.

 

Actividades del grupo

El Servicio de Neurología del Hospital Universitario Cruces, cuenta con una larga tradición en investigación científica y en la atención clínica de máxima calidad de pacientes con Esclerosis Múltiple (EM), que se remonta a 1987 cuando se creó la primera consulta específica de dicha enfermedad de la red de hospitales de Osakidetza.

Los dos objetivos de esta unidad son el asistencial y científico que conviven en estrecha simbiosis y de ellos se nutre nuestra labor investigadora. Durante estos 24 años y de manera ininterrumpida, en el Hospital Universitario Cruces se han llevado a cabo múltiples proyectos de investigación científica sobre la EM.

 

Estos proyectos pueden clasificarse en:

1) la investigación sobre la historia natural de la enfermedad, piedra angular sobre la que se sustentan todos nuestros trabajos científicos. Se lleva a cabo mediante  el estudio y seguimiento de la "cohorte de pacientes de Esclerosis Múltiple de Vizcaya"; una serie poblacional, dinámica, seguida prospectivamente desde hace 24 años.

2) investigación clínica farmacológica mediante la participación en ensayos clínicos internaciones con fármacos en fase II Y III. La mayoría de estos proyectos gestionados por BIOEF.

3) investigación clínica sobre la evolución natural de la enfermedad en determinadas circunstancias (EM y embarazo, EM en pacientes pediátricos, EM y circunstancias relacionadas con el género, EM y co-morbilidad).

4) investigación clínica e integración asistencial con atención primaria mediante el "protocolo Bilbao". Estrategia conjunta de cooperación-comunicación entre distintos niveles asistenciales, en este caso, neurología y atención primaria para mejorar la eficiencia y la calidad asistencial. Así como investigar sobre la comorbilidad de esta patología crónica.

En estos proyectos colaboramos estrechamente con nuestro homónimo del Hospital de Basurto, lo cual incrementa nuestro valor como equipo interhospitalario y nos permite investigar conjuntamente sobre "LaCohortede pacientes de EM de Vizcaya".

Colaboramos con el departamento de neurociencias de la UPV, en concreto con los equipos del Profesor Carlos Matute y del Dr. K. Vandenbroeck.

Coordinador/a del grupo



Miembros del grupo

  Mar Mendibe Bilbao
 
  |   846073 - 946006073
  Susana Mato Santos
 
  Ana Bernal Chico
 
  Jose Eulalio Barcena Llona
 
 
  Sabas Boyero Duran
 
 
  Andrés Mateo Baraibar Sierra
 
  Álvaro Moreno García
 
  Teresa Colomer Molla
 
  Fabrizio Livrone
 
  Maialen Martínez Preciado
 
 
  Ana Moreno Estébanez
 
 
  Ester Sánchez Martín
 

Publicaciones del grupo

Bernal Chico A, Tepavcevic V, Manterola A, Utrilla C, Matute C, Mato S. Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells. Glia. 2022; 71(1): 103-126. DOI:10.1002/glia.24172.

Brieva L, Estruch BC, Merino JAG, Meca Lallana V, Rio J, Rodriguez Antiguedad A, et al. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Mult Scler Relat Disord. 2022; 63: 103805-103805. DOI:10.1016/j.msard.2022.103805.

Garcia M, Rouco Axpe I, Amayra I, Rodriguez Antiguedad A, Catalli C, Cabrera Zubizarreta A, et al. Neuropsychological Profile of Hereditary Ataxias: Study of 38 Patients. Arch Clin Neuropsychol. 2022; 37(5): 904-915. DOI:10.1093/arclin/acac024.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Rodriguez Antiguedad Zarrantz A. Rapid cognitive decline associated with anti-glutamic acid decarboxylase antibodies: a case report. Neurologia (Engl Ed). 2022; 37(2): 151-152. DOI:10.1016/j.nrleng.2021.04.005.

Lopez Soley E, Meca Lallana JE, Llufriu S, Blanco Y, Gomez Ballesteros R, Maurino J, et al. Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. J Pers Med. 2022; 12(5). DOI:10.3390/jpm12050743.

Meca Lallana JE, Gomez Ballesteros R, Perez Miralles F, Forero L, Sepulveda M, Calles C, et al. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study. Neurol Ther. 2022; 11(3): 1101-1116. DOI:10.1007/s40120-022-00356-6.

Saposnik G, Bueno Gil G, Sempere AP, Del Rio Munoz B, Lendinez Mesa A, Azanza Munarriz C, et al. Sick leave and occupational burnout among nurses caring for patients with multiple sclerosis. Mult Scler Relat Disord. 2022; 63: 103916-103916. DOI:10.1016/j.msard.2022.103916.

Ruiz Lopez M, Estebanez M, Tijero B, Fernandez T, Rebollo Perez A, Gabilondo I, et al. Pearls and Oy-sters: Challenges and Controversies in Wilson Disease. Neurology. 2022; 99(6): 251-255. DOI:10.1212/WNL.0000000000200836.

Sanchez de la Torre A, Aguado T, Huerga Gomez A, Santamaria S, Gentile A, Carlos Chara J, et al. Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice. Cell Death Dis. 2022; 13(7). DOI:10.1038/s41419-022-05032-z.

Alonso Torres A, Arevalo Bernabe A, Becerril Rios N, Hellin Gil M, Martinez Sesmero J, Meca Lallana V, et al. Cost-analysis of subcutaneous versus intravenous administration for natalizumab in Multiple Sclerosis in Spain. Eur J Neurol. 2022; 29: 630-631

Meca Lallana JE, Casanova B, Rodriguez Antiguedad A, Eichau S, Izquierdo G, Duran C, et al. Consensus on early detection of disease progression in patients with multiple sclerosis. Front Neurol. 2022; 13: 931014-931014. DOI:10.3389/fneur.2022.931014.

Poyatos Garcia J, Marti P, Liquori A, Muelas N, Pitarch I, Martinez Dolz L, et al. Dystrophinopathy phenotypes and modifying factors in DMD exon 45-55 deletion. Ann Neurol. 2022; 92(5): 793-806. DOI:10.1002/ana.26461.

Baraibar AM, Belisle L, Marsicano G, Matute C, Mato S, Araque A, et al. Spatial organization of neuron-astrocyte interactions in the somatosensory cortex. Cereb Cortex. 2022. DOI:10.1093/cercor/bhac357.

Meca Lallana JE, Fernández Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, et al. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia (Engl Ed). 2022; 37(8): 615-630. DOI:10.1016/j.nrleng.2019.11.001.

Manterola A, Chara JC, Aguado T, Palazuelos J, Matute C, Mato S. Cannabinoid CB1 receptor expression in oligodendrocyte progenitors of the hippocampus revealed by the NG2-EYFP-knockin mouse. Front Neuroanat. 2022; 16: 1030060-1030060. DOI:10.3389/fnana.2022.1030060.

Ramos Gonzalez P, Mato S, Chara JC, Verkhratsky A, Matute C, Cavaliere F. Astrocytic atrophy as a pathological feature of Parkinson's disease with LRRK2 mutation. npj Parkinsons Dis. 2021; 7(1). DOI:10.1038/s41531-021-00175-w.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Rodriguez Antiguedad Zarrantz A. Rapid cognitive decline associated with anti-glutamic acid decarboxylase antibodies: A case repot. Neurologia (Engl Ed). 2021. DOI:10.1016/j.nrl.2021.04.005.

Fernandez O, Montalban X, Aladro Y, Alonso A, Arroyo R, Calles C et al. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (I). Rev Neurologia. 2021; 72(11): 397-406. DOI:10.33588/rn.7211.2021172.

Meca Lallana JE, Prefasi D, Perez Miralles F, Forero L, Sepulveda M, Calles C et al. Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder. Patient Prefer Adherence. 2021; 15: 713-719. DOI:10.2147/PPA.S305707.

Meca Lallana J, Garcia Merino JA, Martinez Yelamos S, Vidal Jordana A, Costa L, Eichau S et al. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegener Dis Manag. 2021; 11(03): 251-261. DOI:10.2217/nmt-2020-0049.

Sifontes Valladares W, Moreno Estebanez A, Diaz Cuervo I, Martin Prieto J, Agirre Beitia G, Cabral Martinez L et al. Autoimmune encephalitis with antibodies against LGI1: broadening the spectrum of dystonic seizures. Eur J Neurol. 2021; 28: 393-393

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Velasco Palacios L, Boyero S, Mendibe Bilbao M et al. Rapid cognitive decline associated with anti-glutamic acid decarboxylase autoantibodies (GAD): a case report. Eur J Neurol. 2021; 28: 562-562

Fernandez O, Montalban X, Aladro Y, Alonso A, Arroyo R, Calles C et al. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (II). Rev Neurologia. 2021; 72(12): 433-442. DOI:10.33588/rn.7212.2021173.

Saposnik G, Bueno Gil G, Sempere AP, Rodriguez Antiguedad A, del Rio B, Baz M et al. Regret and Therapeutic Decisions in Multiple Sclerosis Care: Literature Review and Research Protocol. Front Neurol. 2021; 12. DOI:10.3389/fneur.2021.675520.

Meca Lallana JE, Maurino J, Perez Miralles F, Forero L, Sepulveda M, Calles C et al. Quantifying the patients perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire. PLoS One. 2021; 16(7): 255317-255317. DOI:10.1371/journal.pone.0255317.

Aguado T, Huerga Gomez A, Sanchez de La Torre A, Resel E, Chara JC, Matute C et al. Delta(9)-Tetrahydrocannabinol promotes functional remyelination in the mouse brain. Br J Pharmacol. 2021; 178(20): 4176-4192. DOI:10.1111/bph.15608.

Echeazarra L, del Cano GG, Barrondo S, Gonzalez Burguera I, Saumell Esnaola M, Aretxabala X et al. Fit-for-purpose based testing and validation of antibodies to amino- and carboxy-terminal domains of cannabinoid receptor 1. Histochem Cell Biol. 2021; 156(5): 479-502. DOI:10.1007/s00418-021-02025-5.

Meca Lallana JE, Oreja Guevara C, Muñoz D, Olascoaga J, Pato A, Ramió Torrentà L et al. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. PLoS One. 2021; 16(10). DOI:10.1371/journal.pone.0258437.

Gomez Carballo C, Moreno Estebanez A, Diaz Cuervo I, Fernandez Rodriguez V, Jauregi Barrutia A. Coexistence of antiCASPR2 autoimmune encephalitis, normotensive hydrocephalus and Alzheimer's disease: when Ockham's razor faces clinical practice. Neurol Sci. 2021; 42(11): 4829-4831. DOI:10.1007/s10072-021-05554-y.

Bayon Cordero L, Ochoa Bueno BI, Serrano Regal MP, Tepavcevic V, Capetillo Zarate E, Zallo F et al. GABA(B) receptor downstream mechanisms in OPCs and its role in myelination and remyelination. Glia. 2021; 69: 540-541

Meca Lallana J, Gomez Ballesteros R, Perez Miralles F, Forero L, Sepulveda M, Calles C et al. Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective. J Neurol Sci. 2021; 429: 31-31. DOI:10.1016/j.jns.2021.118844.

Ayuso GI, Guevara CO, Rodriguez EA, Quilez MRB, Lallana VM, Lallana J et al. Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis. Mult Scler J. 2021; 27(2_SUPPL): 274-275

Mena J, Alloza I, Tulloch Navarro R, Aldekoa A, Díez García J, Villanueva Etxebarria A et al. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene Region in Immature Dendritic Cells. Front Immunol. 2021; 12: 816930-816930. DOI:10.3389/fimmu.2021.816930.

Oreja Guevara C, Rio J, Callizo J, Perez M, Gil JG, Torres A et al. Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study. Mult Scler J. 2021; 27(2_SUPPL): 306-307

Meca Lallana V, Rodriguez Antiguedad A, Llaneza MA, Meca Lallana JE. Plasma determination of neurofilaments as biomarkers in multiple sclerosis: conclusions of the EMotion Forum. Rev Neurologia. 2021; 73(3): 101-110. DOI:10.33588/rn.7303.2020691.

Lallana JM, Prefasi D, Casanova B, Diaz LF, Saiz A, Calles C et al. Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study). Neurology. 2021; 96(15)

Saposnik G, Del Rio B, Bueno Gil G, Sempere AP, Lendinez Mesa A, Rodriguez Antiguedad A et al. Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain. PLoS One. 2021; 16(12). DOI:10.1371/journal.pone.0261050.

Miñón Fernández B, Losada Domingo JM, Sánchez Horvath MT, Bárcena Llona J. Miastenia grave asociada a nivolumab. Rev Neurologia. 2020; 70(2): 72-73. DOI:10.33588/rn.7002.2019153.

Moreno Estébanez A, Bilbao Villabeitia I, Echeverria Guibert T, Mendibe Bilbao M, Boyero Durán S, Cabral Martínez L, et al. Positive oligoclonal bands and CSF pleocytosis in narcolepsy type 1: A case report supporting the immune-mediated hypothesis. J Neuroimmunol. 2020; 339: 577111-577111. DOI:10.1016/j.jneuroim.2019.577111.

Meca Lallana JE, Fernández Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, et al. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia. 2020. DOI:10.1016/j.nrl.2019.11.003.

Armangue T, Olivé Cirera G, Martínez Hernandez E, Sepulveda M, Ruiz Garcia R, Muñoz Batista M, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 2020; 19(3): 234-246. DOI:10.1016/S1474-4422(19)30488-0.

Gonzalez Pinto T, Luna Rodriguez A, Moreno Estebanez A, Agirre Beitia G, Rodriguez Antiguedad A, Ruiz Lopez M. Emergency Room Neurology in times of COVID-19: Malignant Ischemic Stroke and SARS-COV2 Infection. Eur J Neurol. 2020; 27(9): 35-36. DOI:10.1111/ene.14286.

Matias Guiu J, Matias Guiu JA, Alvarez Sabin J, Ara JR, Arenillas J, Casado Naranjo I, et al. Will neurological care change over the next 5 years due to the COVID-19 pandemic?. Neurologia. 2020; 35(4): 252-257. DOI:10.1016/j.nrl.2020.04.006.

Moreno Estebanez A, Losada Domingo JM, Gonzalez Pinto Gonzalez T, Rodriguez Antiguedad Zarrantz A. Isolated pseudotumoural demyelination: A focal, monophasic autoimmune encephalitis?. Neurologia. 2020; 35(3): 217-219. DOI:10.1016/j.nrl.2018.01.005.

Fernandez O, Aladro Y, Arroyo R, Brieva LL, Calles Hernandez MC, Carrascal P, et al. [12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I)]. Rev Neurologia. 2020; 70(10): 379-390. DOI:10.33588/rn.7010.2020121.

Fernandez O, Aladro Y, Arroyo R, Brieva LL, Calles Hernandez MC, Carrascal P, et al. 12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II). Rev Neurologia. 2020; 70(11): 417-429. DOI:10.33588/rn.7011.2020122.

Garamendi I, Martinez Gonzalez MJ, Galbarriatu Gutierrez L, Marinas Alejo A, Pomposo Gastelu I, Santos Sanchez C, et al. 20-year experience with Vagus Nerve Stimulation Therapy for drug-resistant epilepsy in a single centre. Eur J Neurol. 2020; 27: 152-152

Beitia GA, Estebanez AM, Gonzalez TGP, Martinez LC, Barrutia AJ, Martinez MF, et al. Neurotoxicity after bupivacaine administration: description of 2 cases. Eur J Neurol. 2020; 27: 743-743

Berriozabalgoitia R, Sanz B, Fraile Bermudez AB, Otxoa E, Yeregui I, Bidaurrazaga Letona I, et al. An Overground Robotic Gait Training Program for People With Multiple Sclerosis: A Protocol for a Randomized Clinical Trial. Front Med (Lausanne). 2020; 7. DOI:10.3389/fmed.2020.00238.

Moreno Garcia A, Bernal Chico A, Colomer T, Rodriguez Antiguedad A, Matute C, Mato S. Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination. Biomolecules. 2020; 10(9). DOI:10.3390/biom10091228.

Rio J, Pena J, Ruiz LB, Oreja Guevara C, Costa Frossard L, Rodriguez Antiguedad A, et al. Assessment and Follow-up of the Response to Disease Modifying Treatments in Multiple Sclerosis: Spanish Expert Consensus. Neurology. 2020; 94(15)

Otero Romero S, Rodriguez Garcia J, Vilella A, Ara JR, Brieva L, Calles C, et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia. 2020; 36(1): 50-60. DOI:10.1016/j.nrl.2020.02.006.

Habbane M, Llobet L, Bayona Bafaluy MP, Barcena JE, Ceberio L, Gomez Diaz C, et al. Leigh Syndrome in a Pedigree Harboring the m.1555A>G Mutation in the Mitochondrial 12S rRNA. Genes. 2020; 11(9). DOI:10.3390/genes11091007.

Huerga Gomez A, Aguado T, Sanchez de la Torre A, Bernal Chico A, Matute C, Mato S, et al. Delta9 -Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo. Glia. 2020; 69(3): 532-545. DOI:10.1002/glia.23911.

Calovi S, Mut Arbona P, Tod P, Iring A, Nicke A, Mato S, et al. P2X7 Receptor-Dependent Layer-Specific Changes in Neuron-Microglia Reactivity in the Prefrontal Cortex of a Phencyclidine Induced Mouse Model of Schizophrenia. Front Molec Neurosci. 2020; 13. DOI:10.3389/fnmol.2020.566251.

Agirre Beitia G, Moreno Estebanez A, Gonzalez TGP, Jimenez BM, Rodriguez IC, Martinez LC, et al. FOSMN A possible TDP-43 proteinopathy to consider in a patient with facial sensory symptoms. Neurol-Clin Pract. 2020; 10(5): 47-50. DOI:10.1212/CPJ.0000000000000753.

Oreja Guevara C, Rio J, Ara Callizo JR, Hernandez Perez MA, Gracia Gil J, Ramio I Torrenta L, et al. Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study. Mult Scler J. 2020; 26(3_SUPPL): 603-604

Oreja Guevara C, Casanova Estruch B, Garcia Merino JA, Costa Frossard L, Fernandez Uria D, Ara JR, et al. Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients. Mult Scler J. 2020; 26(3_SUPPL): 240-241

Mendibe Bilbao M, Boyero Durán S, Bárcena Llona J, Rodriguez Antigüedad A. Multiple sclerosis: Pregnancy and women's health issues. Neurologia. 2019; 34(4): 259-269. DOI:10.1016/j.nrl.2016.06.005.

Garamendi I, Garcia Martinez A, Matute Nieves A, Garcia Rua A, Marinas Alejo A, Suarez Santos P, et al. One-year clinical experience with brivaracetam in spain: Study of the efficacy and tolerability. Eur J Neurol. 2019; 26: 131-131

Fernandez O, Tintore M, Saiz A, Carmen Calles Hernandez M, Comabella M, Ramio Torrenta L, et al. Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (I). Rev Neurologia. 2019; 68(10): 431-441. DOI:10.33588/rn.6810.2019120.

Fernandez O, Tintore M, Saiz A, Carmen Calles Hernandez M, Comabella M, Ramio Torrenta L, et al. Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II). Rev Neurologia. 2019; 68(11): 468-479. DOI:10.33588/rn.6811.2019121.

Vilarino Guell C, Zimprich A, Martinelli Boneschi F, Herculano B, Wang Z, Matesanz F, et al. Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. PLoS Genet. 2019; 15(6). DOI:10.1371/journal.pgen.1008180.

Fernadez Fernandez O, Rodriguez Antiguedad A, Aboin Sierra J. Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: real-world results - interim results of second year follow-up. Mult Scler J. 2019; 25: 764-765

Rio J, Brieva L, Costa Frossard L, Garcia Dominguez JM, Oreja Guevara C, Pena J, et al. Assessment and follow-up of the response to disease modifying treatments in multiple sclerosis: Spanish expert consensus. Mult Scler J. 2019; 25: 784-785

Oreja Guevara C, García Merino JA, Saiz A, Rodríguez Antigüedad A, Álvarez Cermeño JC, Estrada Pérez V, et al. Recomendaciones de uso de cladribina comprimidos en la esclerosis múltiple recurrente. Rev Neurologia. 2019; 69(s02): 1-9. DOI:10.33588/rn.69s02.2019380.

Oreja Guevara C, Garcia Merino JA, Saiz A, Rodriguez Antiguedad A, Alvarez Cermeno JC, Estrada Perez V, et al. Recommendations for the use of cladribine tablets in recurring multiple sclerosis. Rev Neurologia. 2019; 69(2): 1-9

Rilo O, Peña J, Ojeda N, Rodríguez Antigüedad A, Mendibe Bilbao M, Gómez Gastiasoro A, et al. Integrative group-based cognitive rehabilitation efficacy in multiple sclerosis: a randomized clinical trial. Disabil Rehabil. 2018; 40(2): 208-216. DOI:10.1080/09638288.2016.1250168.

Fernandez O, Rodriguez Antiguedad A, Cadima R, Botella I. Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: real-world results and initial results of first year follow-up. Mult Scler J. 2018; 24(2): 930-930

Cortes Vicente E, Rojas Garcia R, Diaz Manera J, Querol L, Casasnovas C, Guerrero Sola A, et al. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol. 2018; 5(6): 710-716. DOI:10.1002/acn3.564.

Fernandez O, Tintore M, Saiz A, Calles Hernandez MC, Comabella M, Ramio Torrenta L, et al. Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (I). Rev Neurologia. 2018; 67(1): 15-27. DOI:10.33588/rn.6701.2018192.

Fernandez O, Tintore M, Saiz A, Calles Hernandez MC, Comabella M, Ramio Torrenta L, et al. Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post- ECTRIMS Meeting ( II). Rev Neurologia. 2018; 67(2): 50-62. DOI:10.33588/rn.6702.2018193.

Alerany C, Fernandez R, Landete L, Rodriguez A, Sandoval S, Valdivia M, et al. DETERMINING THE VALUE OF OCREVUS (R) (OCRELIZUMAB) FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA). Value Health. 2018; 21(3): 345-345. DOI:10.1016/j.jval.2018.09.2064.

Gabilondo I, Rilo O, Ojeda N, Pena J, Gómez Gastiasoro A, Mendibe Bilbao M, et al. The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis. Mult Scler J. 2017; 23(9): 1276-1288. DOI:10.1177/1352458516676642.

Cipriani R, Chara JC, Rodriguez Antiguedad A, Matute C. Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury. J Neuroinflamm. 2017; 14. DOI:10.1186/s12974-017-0922-6.

Fernandez O, Oterino A, Oreja Guevara C, Prieto JM, Mendibe Bilbao MD, Garcia Merino JA, et al. Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II). Rev Neurologia. 2017; 65(2): 75-84. DOI:10.33588/rn.6502.2017169.

Fernandez O, Oterino A, Oreja Guevara C, Prieto JM, Mendibe Bilbao MD, Garcia Merino JA, et al. Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I). Rev Neurologia. 2017; 65(1): 31-40. DOI:10.33588/rn.6501.2017168.

Caro SV, Antiguedad AR, Bilbao MM, Caro PV. NeuronUp as a tool for Cognitive Rehabilitation in MS. Mult Scler J. 2017; 23(6): 882-882

Rilo O, Ojeda N, Pena J, Cabrera A, Rodriguez Antiguedad A, Mendibe Bilbao M, et al. Maintenance of the default mode network functional connectivity through an integrative group-based cognitive rehabilitation in multiple sclerosis. Mult Scler J. 2017; 23(6): 891-891

Rilo O, Pena J, Gomez Gastiasoro A, Ibarretxe Bilbao N, Del Pino R, Rodriguez Antiguedad A, et al. Estimation of verbal memory and processing speed cognitive performance according to premorbid intelligence in multiple sclerosis patients Running tittle: Estimation of cognitive performance in MS. Mult Scler J. 2017; 23(6): 905-905

Sepúlveda M, Armangué T, Sola Valls N, Arrambide G, Meca Lallana JE, Oreja Guevara C, et al. Neuromyelitis optica spectrum disorders Comparison according to the phenotype and serostatus. Neurol-Neuroimmunol Neuroinflammation. 2016; 3(3). DOI:10.1212/NXI.0000000000000225.

Meca Lallana J, Mendibe M, Hernandez Clares R, Belen Caminero A, Mallada Frechin J, Davila Gonzalez P, et al. Predictors of burden and depression among caregivers of relapsing-remitting MS patients in Spain: MS Feeling study. Neurodegener Dis Manag. 2016; 6(4): 277-287. DOI:10.2217/nmt-2016-0014.

Fernandez O, Rodriguez Antiguedad A, Olascoaga J, Oreja Guevara C, Prieto JM, Mendibe Bilbao MM, et al. Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Rev Neurologia. 2016; 62(12): 559-569. DOI:10.33588/rn.6212.2016196.

Rilo O, Pena J, Natalia O, Rodriguez Antiguedad A, Mendibe Bilbao M, Cabrera A, et al. Cognitive improvement and functional connectivity changes after integrative group-based cognitive rehabilitation in multiple sclerosis. Mult Scler J. 2016; 22(3): 41-41

Agundez M, Rouco I, Barcena J, Mateos B, Barredo J, Zarranz JJ. Hirayama disease: Is surgery an option?. Neurologia. 2015; 30(8): 502-509. DOI:10.1016/j.nrl.2013.05.005.

Meca Lallana J, Mendibe M, Hernandez Clares R, Caminero AB, Mallada J, Davila P, et al. Burden and depression in caregivers and patients with multiple sclerosis. MS-feeling study. Mult Scler J. 2015; 21(11): 338-338

Mendibe M, Boyero S, Llarena C, Rodriguez Antigueedad A. Demographic and clinical profile of PEDIATRIC patients with multiple sclerosis: descriptive analysis of a prospective monitored, population-based cohort study in the Basque Country (Spain). Mult Scler J. 2015; 21(11): 97-97

Rilo O, Pena J, Ojeda N, Rodriguez Antigueedad A, Mendibe Bilbao M, Gomez Gastiasoro A, et al. Integrative group-based cognitive rehabilitation efficacy in multiple sclerosis. Mult Scler J. 2015; 21(11): 230-231

Querol Gutierrez LA, Rojas Garcia R, Diaz Manera J, Barcena J, Pardo Fernandez J, Ortega Moreno A, et al. Rituximab is effective in treatment-resistant CIDP with IgG4 antibodies against paranodal proteins. Eur J Neurol. 2015; 22(1, SI): 39-39

Querol Gutierrez LA, Rojas Garcia R, Diaz Manera J, Barcena J, Pardo Fernandez J, Ortega Moreno A, et al. RITUXIMAB IS EFFECTIVE IN TREATMENT-RESISTANT CIDP WITH IGG4 ANTIBODIES AGAINST PARANODAL PROTEINS. J Peripher Nerv Syst. 2015; 20(2): 214-215

Gabilondo I, Rilo O, Ojeda N, Pena J, Gomez A, Mendibe M, et al. Visual information processing speed and the damage to posterior visual pathway in multiple sclerosis. Mult Scler J. 2015; 21(11): 50-50

Rilo O, Pena J, Ojeda N, Gomez Gastiasoro A, Mendibe Bilbao M, Rodriguez Antigueedad A, et al. The role of processing speed in multiple sclerosis cognitive impairment. Mult Scler J. 2015; 21(11): 520-521

Rodriguez Antigueedad Zarranz A, Mendibe Bilbao M, LLARENA GONZALEZ MC, Audicana C. Mortality and Cause of Death in Multiple Sclerosis: Findings from a Prospective Population-Based Cohort in Bizkaia, Basque Country, Spain. Neuroepidemiology. 2014; 42(4): 219-225. DOI:10.1159/000359971.

Fernandez O, Alvarez Cermeno JC, Arnal Garcia C, Arroyo Gonzalez R, Brieva L, Carmen Calles Hernandez M, et al. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurologia. 2014; 59(6): 269-280. DOI:10.33588/rn.5906.2014321.

Fernandez O, Alvarez Cermeno JC, Arnal Garcia C, Arroyo Gonzalez R, Brieva L, Carmen Calles Hernandez M, et al. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurologia. 2014; 59(7): 307-316. DOI:10.33588/rn.5907.2014334.

Fernandez O, Alvarez Cermeno JC, Arnal Garcia C, Arroyo Gonzalez R, Brieva L, Carmen Calles Hernandez M, et al. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurologia. 2014; 59(8): 371-379. DOI:10.33588/rn.5908.2014335.

Balana M, Fabregas M, Meca Lallana J, Mendibe M, Garcia E. FACTORS ASSOCIATED WITH CAREGIVER'S BURDEN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS AND SATISFACTION WITH CURRENT THERAPIES. MS-FEELING STUDY. Value Health. 2014; 17(7): 402-402. DOI:10.1016/j.jval.2014.08.920.

Meca Lallana J, Mendibe M. Stress burden and satisfaction with treatment in caregivers and patients with multiple sclerosis. MS-feeling study. Mult Scler J. 2014; 20(1): 392-392

Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81:1500-6. FI: 8,249(Q1)

Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al; Post-ECTRIMS Group. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurologia. 2013;57:317-29. FI: 1,179(Q4)

Antigueedad A, Llarena C, Mendibe M. Mortality and cause of death in multiple sclerosis: findings from a prospective population-based cohort in Bizkaia, Spain. Mult  Scler J. 2013;19:97. FI: 4,472(Q1)

Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al; Post-ECTRIMS Group. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurologia. 2013;57:269-81. FI: 1,179(Q4)

Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, et al; Post-ECTRIMS Group. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurologia. 2013;57:217-29. FI: 1,179(Q4)

Agundez M, Rouco I, Barcena J, Mateos B, Barredo J, Zarranz JJ. Hirayama disease: Is surgery an option?. Neurologia 2013; -0. FI: 1,322(Q3)

Sepúlveda M, Blanco Y, Rovira A, Rio J, Mendibe M, Llufriu S, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler  J. 2013;19:742-8. FI: 4,472(Q1)

 

Tesis del grupo

Autor/a: Andrea Manterola Juaristi. Título: "Therapeutic potencial of the endocannabinoid system in multiple sclerosis: novel clues from oligodendrocyte CB1 receptors and ABHD6/Endokannabinoide sistemaren potentzial terapeutikoa esklerosi anizkoitzean: Oligodendrozitoetako CB1 hartzaileen eta ABHD". Directores/as: Dr. Carlos Matute Almao, Dra. Susana Mato Santos.

© 2022 IIS Biocruces Bizkaia